Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to release its earnings data after the market closes on Monday, February 12th. Analysts expect Neurocrine Biosciences to post earnings of ($0.10) per share for the quarter.
Neurocrine Biosciences (NASDAQ NBIX) opened at $83.33 on Monday. The firm has a market capitalization of $7,374.12, a price-to-earnings ratio of -37.54, a P/E/G ratio of 13.81 and a beta of 0.26. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 52-week low of $39.21 and a 52-week high of $91.82.
In other news, insider Dimitri E. Grigoriadis sold 30,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the insider now directly owns 77,691 shares of the company’s stock, valued at $5,794,194.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Darin Lippoldt sold 9,900 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total value of $723,195.00. The disclosure for this sale can be found here. Insiders sold 106,462 shares of company stock worth $8,104,607 over the last ninety days. Insiders own 4.80% of the company’s stock.
Several research firms recently weighed in on NBIX. BidaskClub upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. Barclays boosted their price objective on Neurocrine Biosciences from $75.00 to $85.00 and gave the company an “overweight” rating in a research report on Thursday, November 2nd. Leerink Swann restated an “outperform” rating and issued a $83.00 price objective (up from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Citigroup restated a “buy” rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, BMO Capital Markets boosted their price objective on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Neurocrine Biosciences currently has an average rating of “Buy” and a consensus target price of $82.31.
WARNING: “Neurocrine Biosciences (NBIX) Scheduled to Post Earnings on Monday” was published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/05/neurocrine-biosciences-nbix-scheduled-to-post-earnings-on-monday.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.